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Abstract 
Based on a 10-year systematic review of suicide prevention strategies, 29 suicide prevention 
experts from 17 European countries recommend four allegedly evidence-based strategies to 
be included in national suicide prevention programs. One of the recommended strategies is 
pharmacological treatment of depression. This recommendation is problematic for several 
reasons. First, it is based on a biased selection and interpretation of available evidence. 
Second, the authors have failed to take into consideration the widespread corruption in the 
research on antidepressants. Third, the many and serious side effects of antidepressants are 
not considered. Thus, the recommendation may have deleterious consequences for countless 
numbers of people, and, in fact, contribute to an increase in the suicide rate rather than a 
decrease. 
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Problematic advice from suicide prevention experts 
In the paper, Evidence-based national suicide prevention taskforce in Europe: A 
consensus position paper, “29 suicide prevention experts from 17 European countries” 
(Zalsman et al. 2017, p. 419) list four allegedly evidence-based strategies that should be 
included in national suicide prevention programs: (a) Restriction of access to lethal means, 
(b) treatment of depression (pharmacotherapy and psychotherapy), (c) ensuring chain of care, 
and (d) school-based universal prevention (Zalsman et al., 2017). These strategies are based 
on a 10-year systematic review of suicide prevention strategies conducted by “18 suicide 
prevention experts” (Zalsman et al., 2016), 15 of which overlap with the experts authoring 
the consensus position paper. Together, the terms evidence-based, consensus, and suicide 
prevention experts convey an authoritative message others are likely to follow and 
governments to fund. In this paper, we demonstrate that the authors make a number of 
problematic assumptions with regard to the view that pharmacological treatment of 
depression should be included in national suicide prevention strategies.  
 
The review constituting the evidence base is biased 
Zalsman et al.’s (2016) review is biased in that it does not include the numerous 
studies or reviews not supporting the authors’ recommendation. For instance, ecological 
studies that have found an inverse correlation between use of antidepressants and the suicide 
rate are included (Gusmao et al., 2013). Ecological studies finding no such relationship are 
excluded (Zahl, De Leo, Ekeberg, Hjelmeland & Dieserud, 2010). Moreover, Zahl et al. 
(2010) showed that some of the studies claiming to have found that increased sales of 
antidepressants was associated with a decrease in the suicide rate were flawed. Most 
importantly, however, is that ecological studies cannot say anything about causal effects and 
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can therefore not constitute any valid evidence base for recommending use of antidepressants 
to prevent suicide.  
Randomized controlled trials (RCTs) are normally considered gold standard studies 
with regard to demonstrating treatment effects of medications, and the review by Zalsman et 
al. (2016) includes some RCTs and reviews of the same. Again, the review seems selective. 
For instance, it does not include Fergusson et al.’s (2005) systematic review of 702 RCTs 
finding that the rate of attempted suicide increased more than twofold in patients receiving 
selective serotonin reuptake inhibitors (SSRIs) compared with placebo or other treatments. 
Fergusson et al. (2005) also point out several methodological problems with the published 
trials (discussed further below).  
What is also missing from the Zalsman et al. (2016) review is the meta-analysis 
conducted by the US Food and Drug Administration (FDA; Stone et al. 2009). This review 
found the risk of suicidality associated with the use of antidepressants to be highly age-
dependent. There was an increased risk for suicidality among adults under 25; no effect for 
the age group 25-64; and a reduced suicide risk in those aged 65 years and over. This study 
has later come under scrutiny. According to Gøtzsche (2015), the FDA actually found 
increased risk of suicidal behaviour for those up to 40 years of age but decided to split age 
groups differently when publishing the data to make it appear as if the increased risk was for 
young people only.   
With regard to children and adolescents, Högberg, Antonuccio and Healy (2015) 
showed that the risk for suicidal behaviour in the Treatment of Adolescents with Depression 
Study (TADS) was higher than it first appeared among the adolescents treated with 
antidepressants compared to the placebo group. Healy (2007), in a paper pertinently titled 
One flew over the conflict of interest nest, maintained that “the greatest known divide in 
medicine between the raw data on an issue on the one side and the published accounts 
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purporting to represent those data on the other” (Healy, 2007, p. 26), concerns paediatric 
trials on SSRIs. Published and unpublished data taken together indicate that SSRIs do not 
work and are also hazardous (Healy, 2007). Still, Zalsman et al. (2016) maintain, “In children 
and adolescents with depression, evidence does not support avoidance of use of 
antidepressant medication because of increased risk of suicidal behaviour.”  
 
Problems related to RCTs on antidepressants are not considered  
There are several problems connected to RCTs and the effect of antidepressants on 
suicidality. Some are methodological in nature, for instance, non-effective blinding of trials. 
Since antidepressants have conspicuous side effects, patients and doctors will know whether 
the drug is an antidepressant or a placebo (Gøtzsche, 2015). Others are tied to widespread 
corruption (Gøtzsche, 2015). Sometimes the two sets of problems are intertwined. Zalsman et 
al. (2017) fail to take into consideration the well-documented fact that pharmaceutical 
companies and their allies in psychiatry have contributed to a publication bias in favour of 
antidepressants with regard to suicide (Gøtzsche, 2013; Gøtzsche, 2015; Healy, 2008). In a 
landmark study of 74 FDA-registered RCTs, Turner, Matthews, Linardatos, Tell and 
Rosenthal (2008) showed that, with very few exceptions, RCTs finding negative or 
questionable effects of antidepressants were either not published, or published in a way that 
made the outcome seem positive. All but one study finding positive effects were published. 
Gøtsche (2015) argues that fraud more broadly, and unethical practices in particular, 
contribute to the underestimation of suicidal risk in RCTs. What follows is his summary of 
these problems: Some of these practices include researchers not reporting suicide attempts 
during trials. When attempts are reported, they are coded as something else (e.g. an 
overdose). Furthermore, companies often include people with very low risk of suicide. 
Sometimes trials have initial periods with participants on active medication and then exclude 
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participants displaying pronounced side effects before the actual trial. Sometimes participants 
are on antidepressant treatment before they are randomized, which then leads to withdrawal 
symptoms (due to cold turkey termination of the antidepressant) in the placebo group that, in 
turn, increases the risk of suicide. Thus, the difference between the groups with regard to 
suicide is minimized. Companies sometimes also encourage researchers to prescribe 
benzodiazepines in addition to the antidepressant to avoid some of the more pronounced side 
effects. Still further, suicidal behaviour shortly after the active treatment is not recorded. 
Participants may be followed closely in the trials, but the antidepressant may be terminated 
before a serious problem develops. In clinical practice, it is not possible to follow the patients 
so closely, and they can forget to take their medicine. This may, in turn, increase the risk of 
suicide due to withdrawal symptoms (Gøtzsche, 2015).  
Healy (2006) has shown how both the FDA and pharmaceutical companies have 
manipulated data and its statistical analyses to get the results they wanted. One clear example 
is Study 329. This was a double-blind RCT study to evaluate the efficacy and safety of an 
SSRI (paroxetine) for adolescents with major depression. Funded by GlaxoSmithKline 
(GSK), this study was, according to Healy (2008), largely ghost-written. The reported results 
indicated that paroxetine was effective and safe (Keller et al., 2001). It was later revealed that 
in 1998, GSK already had concluded that the drug in question did not work, but that 
“positive” aspects should be selected for publication (Healy, 2008). Under the “restoring 
invisible and abandoned trials” (RIAT) initiative, Study 329 was recently reanalysed with the 
results now showing that paroxetine was not effective for major depression and that the drug 
actually had a number of serious adverse effects, including those related to suicide (Le Noury 
et al., 2015). 
Gøtzsche (2013, 2015) also documents that on several occasions the FDA protected 
pharmaceutical companies rather than the participants in the RCTs. Based on his calculations 
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of published and unpublished data, he maintains that the actual number of suicides connected 
to the use of antidepressants probably are 15 times higher than what was reported by the 
FDA, all of which amounts to an error of 1.400% (Gøtzsche, 2015). Based on this massive 
underreporting of suicide, he concludes that SSRIs most likely increase the prevalence of 
suicide in all ages (Gøtzsche, 2015).  
 
Harmful side effects are not considered  
Zalsman et al. (2017) also fail to consider the serious consequences in terms of 
harmful side effects of antidepressants. Among others, Gøtzsche (2015) has extensively 
documented how a corrupt pharmaceutical industry has systematically denied or toned down 
harmful side effects of antidepressants (e.g. Study 329). In their systematic review of 
published versus unpublished data on SSRIs, Whittington et al. (2004) found that whereas the 
published data suggested a favourable risk-benefit profile, the addition of unpublished data 
indicated that the risks could outweigh the benefits in the treatment of depression in children 
and adolescents.  
In their review of antidepressant studies, Antonuccio and Healy (2012) conclude that 
so-called antidepressants: 1) are not more effective than placebo in relieving depression for 
the vast majority of people who take them, 2) do not offer a risk/benefit balance exceeding 
that of alternatives, 3) may increase suicidality, 4) increase anxiety and agitation, 5) interfere 
with sexual functioning, and, 6) increase depression chronicity. Based on all this, they argue 
that antidepressants do not even justify their label since many of the side effects actually have 
larger effect sizes in studies than do the antidepressants. Thus, according to Antonuccio and 
Healy (2012), they could just as well be called antiaphrodisiacs because of the very common 
negative effects on libido and sexual functioning. 
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In a more recent review and meta-analysis of clinical study reports, Sharma, Guski, 
Freund, and Gøtzsche (2016) revealed discrepancies in reporting, which may have led to a 
serious underreporting of harmful side effects. Still, they found that the risk of suicidality and 
aggression doubled for children and adolescents who took antidepressants in comparison to 
the placebo group. Given that these side effects are commonly known, it is particularly 
strange that Zalsman et al. (2017) did not account for them. Alongside suicidality, some of 
the side effects include: violent behaviour (including murder); making a depressive episode 
chronic that otherwise would most likely have passed by itself; psychosis; anxiety; agitation; 
akathisia; sexual dysfunction; hostility; loss of emotion; lethargy; not feeling like oneself; 
loss of creativity; nausea; headaches; sweating; dizziness; confusion; cramps; memory loss; 
sleeping problems; and dependency of medication (Antonuccio & Healy, 2012; Gøtzsche, 
2015). This begs the following question: if antidepressants do in fact produce all these side 
effects detrimental to the well-being of a person, will their prescription actually increase 
suicidality?  
 
The basis for the experts’ recommendation is flawed 
The basis for Zalsman et al.’s (2017) recommendation is the assumption that suicide 
is caused by, or a consequence of mental disorder, mainly depression. The belief is that if we 
treat the depression, the person will no longer be suicidal. Unfortunately, this is not 
necessarily the case. First, the so-called evidence-base for the strong connection between 
mental disorder and suicide, with its inherent causal implications, is weak (Hjelmeland, 
Dieserud, Dyregrov, Knizek, & Leenaars, 2012). It mainly consists of findings from 
psychological autopsies that are fraught with methodological problems, particularly with 
regard to the diagnostic process. Hence, it cannot constitute any valid evidence-base for the 
often-cited 90 per cent statistic, namely that at least 90 per cent of suicides are related to a 
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mental disorder (Hjelmeland et al., 2012). Second, as qualitative suicide research has 
burgeoned, the strong association between mental disorder and suicide has come under 
further scrutiny. Qualitative studies contextualizing suicide indicate that suicide is more 
connected to existential and contextual issues than to mental disorder (Hjelmeland & Knizek, 
2016; White, Marsh, Kral, & Morris, 2016). Medicalizing existential problems or contextual 
issues is highly problematic.  
 
The consensus claim is misleading 
To make a statement regarding consensus might simply mean that a group of people 
has agreed on something without any further implications. However, when consensus is 
mentioned in connection with “evidence based strategies for suicide prevention”, 
recommended by “suicide prevention experts” (29 of them, with some holding influential 
positions), we expect quite a few readers will interpret this to mean that the suicide 
prevention expert community has agreed on what is best to do to prevent suicide.  
  To give the impression that there is consensus in the field of suicide prevention is very 
misleading. Due to suicide’s complexity, there is not, and probably never will be, consensus 
in the field of suicidology. Arguably, consensus may very well be uncalled for, or not 
desirable if it means producing a “one-size fits all”-strategy of suicide prevention. There is 
far too much variety with regard to individual as well as contextual factors connected to 
suicidality (Hjelmeland & Knizek, 2016). Instead of being seen as a weakness, disagreements 
between professionals working in the field of suicide prevention should be considered a 
strength and embraced as a basis for fruitful discussions for the purpose of responding to 
suicide more effectively and moving forward the field of suicidology. Unfortunately, voices 
critical of mainstream versions of suicidology are often unwelcome by influential 
professionals such as researchers in leading positions and journal editors (Healy, 2008; 
PROBLEMATIC ADVICE FROM SUICIDE PREVENTION EXPERTS 
 
9 
Hjelmeland & Knizek, 2017; Kirsch, 2008). This hinders not only the maintenance of open 
debates, but also the development of the field of suicidology, where publications repeatedly 
do nothing more than repeat the status quo (Hjelmeland, 2016).  
 
Conclusion 
Most antidepressants are prescribed by general practitioners (GPs), often without 
noting a psychiatric diagnosis, which means they are often prescribed not for a formal 
diagnosis of depression, but for symptoms of depression only (Mojtabai & Olfson, 2011). 
GPs may or may not at the same time refer the patient to psychological treatment. Either way, 
waiting lists for psychologists are normally quite long, or, as is the case in many low and 
middle-income countries, psychologists may virtually be inaccessible. Besides, prescription 
of antidepressants appears much cheaper and is therefore likely to be embraced by patients as 
well as governments as the first, and probably often the only choice.  
If antidepressants indeed have little effect on depression and/or suicidality, but a 
number of serious side effects, some of which actually may increase the risk of suicide 
(Antonuccio & Healy, 2012; Gøtzsche, 2015; Sharma et al., 2016; Whittington et al., 2004), 
Zalsman et al.’s (2017) recommendation is not supported. It is not evidence-based; it is based 
on a biased selection and interpretation of available evidence. Moreover, the authors have 
failed to take into consideration the widespread corruption in the research on antidepressants, 
as well as the many and serious side effects of SSRIs. Without reservation, they recommend 
pharmacological treatment of depression as one of the four “evidence-based strategies” that 
should be included in national suicide prevention programs. This may have deleterious 
consequences for countless numbers of people, and, in fact, contribute to an increase in the 
suicide rate rather than a decrease.  
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